{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:40:58Z","timestamp":1783960858360,"version":"3.55.0"},"reference-count":165,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The management of hemophilia A has undergone a remarkable revolution, in line with technological advancement. In the recent past, the primary concern associated with Factor VIII (FVIII) concentrates was the risk of infections, which is now almost resolved by advanced blood screening and viral inactivation methods. Improving patients' compliance with prophylaxis has become a key focus, as it can lead to improved health outcomes and reduced health care costs in the long term. Recent bioengineering research is directed toward prolonging the recombinant FVIII (rFVIII) coagulant activity and synthesising higher FVIII yields. As an outcome, B-domain deleted, polyethylene glycolated, single-chain, Fc-fused rFVIII, and rFVIIIFc-von Willebrand Factor-XTEN are available for patients. Moreover, emicizumab, a bispecific antibody, is commercially available, whereas fitusiran and tissue factor pathway inhibitor are in clinical trial stages as alternative strategies for patients with inhibitors. With these advancements, noninfectious complications, such as inhibitor development, allergic reactions, and thrombosis, are emerging concerns requiring careful management. In addition, the recent approval of gene therapy is a major milestone toward a permanent cure for hemophilia A. The vast array of treatment options at our disposal today empowers patients and providers alike, to tailor therapeutic regimens to the unique needs of each individual. Despite significant progress in modern treatment options, these highly effective therapies are markedly more expensive than conventional replacement therapy, limiting their access for patients in developing countries.<\/jats:p>","DOI":"10.1055\/s-0043-1778103","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T23:46:07Z","timestamp":1705362367000},"page":"695-713","source":"Crossref","is-referenced-by-count":13,"title":["Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment"],"prefix":"10.1055","volume":"50","author":[{"given":"Rubhan","family":"Chandran","sequence":"additional","affiliation":[{"name":"Department of Pathology, Haematology Unit, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia"},{"name":"Faculty of Pharmaceutical Sciences, Department of Pharmaceutical Biology, UCSI University, Jalan Puncak Menara Gading, Taman Connaught, Cheras, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eusni R. Mohd.","family":"Tohit","sequence":"additional","affiliation":[{"name":"Department of Pathology, Haematology Unit, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnson","family":"Stanslas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pharmacotherapeutics Unit, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norazlinaliza","family":"Salim","sequence":"additional","affiliation":[{"name":"Centre of Foundation Studies for Agricultural Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia"},{"name":"Integrated Chemical Biophysics Research, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan M.T.","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, The National University of Malaysia (UKM), Jalan Raja Muda Abdul Aziz, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogana","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Department of Pharmaceutical Biology, UCSI University, Jalan Puncak Menara Gading, Taman Connaught, Cheras, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/JBM.S82457","article-title":"Potential role of a new PEGylated recombinant factor VIII for hemophilia A","volume":"7","author":"T T Wynn","year":"2016","journal-title":"J Blood Med"},{"issue":"23","key":"ref3","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJM200106073442301","article-title":"Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A","volume":"344","author":"D A Roth","year":"2001","journal-title":"N Engl J Med"},{"issue":"23","key":"ref4","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2013from royal genes to gene therapy","volume":"344","author":"P M Mannucci","year":"2001","journal-title":"N Engl J Med"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nrg1617","article-title":"Haemophilia A: from mutation analysis to new therapies","volume":"6","author":"J Graw","year":"2005","journal-title":"Nat Rev Genet"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"S C Gouw","year":"2013","journal-title":"N Engl J Med"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3324\/haematol.2019.232132","article-title":"Hemophilia therapy: the future has begun","volume":"105","author":"P M Mannucci","year":"2020","journal-title":"Haematologica"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"F Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"ref10","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5\u2013factor VIII gene transfer in severe hemophilia A","volume":"377","author":"S Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"issue":"09","key":"ref11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40265-023-01866-9","article-title":"Efanesoctocog alfa: first approval","volume":"83","author":"S J Keam","year":"2023","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/hum.2023.29251.bfs","article-title":"BioMarin's ROCTAVIAN wins food and drug administration approval as first gene therapy for severe hemophilia A","volume":"34","author":"A Philippidis","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"03","key":"ref14","first-page":"279","article-title":"The increased demand for plasma-derived factor VIII in Italy","volume":"15","author":"R Arcieri","year":"2017","journal-title":"Blood Transfus"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.transci.2018.07.012","article-title":"The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A","volume":"57","author":"B Kevane","year":"2018","journal-title":"Transfus Apheresis Sci"},{"issue":"06","key":"ref16","first-page":"e26015","article-title":"The impact of recombinant versus plasma-derived factor VIII concentrates on inhibitor development in previously untreated patients with hemophilia A: a 2021 update of a systematic review and meta-analysis","volume":"14","author":"K Kohar","year":"2022","journal-title":"Cureus"},{"issue":"08","key":"ref17","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1080\/13696998.2018.1468335","article-title":"Cost analysis of plasma-derived factor VIII\/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States","volume":"21","author":"E J Neufeld","year":"2018","journal-title":"J Med Econ"},{"issue":"21","key":"ref18","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"F Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jth.13888","article-title":"Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis","volume":"16","author":"F Peyvandi","year":"2018","journal-title":"J Thromb Haemost"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.thromres.2020.12.004","article-title":"Incidence of inhibitor development in PUPs with severe haemophilia A in the CEE region between 2005 and 2015","volume":"198","author":"J Blatn\u00fd","year":"2021","journal-title":"Thromb Res"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1089\/hum.2017.167","article-title":"Advances in gene therapy for hemophilia","volume":"28","author":"A C Nathwani","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/trf.12423","article-title":"Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates","volume":"54","author":"R Klamroth","year":"2014","journal-title":"Transfusion"},{"issue":"06","key":"ref23","first-page":"525","article-title":"Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia","volume":"16","author":"A Farrugia","year":"2018","journal-title":"Blood Transfus"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0049-3848(99)00031-6","article-title":"The gene expression of coagulation factor VIII in mammalian cell lines","volume":"95","author":"C Chen","year":"1999","journal-title":"Thromb Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.thromres.2010.01.044","article-title":"Future directions in hemostasis: normalizing the lives of patients with hemophilia","volume":"125","author":"M E Carr Jr","year":"2010","journal-title":"Thromb Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/JBM.S103796","article-title":"Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?","volume":"8","author":"K Lieuw","year":"2017","journal-title":"J Blood Med"},{"issue":"08","key":"ref27","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood.V98.8.2571","article-title":"TT virus contaminates first-generation recombinant factor VIII concentrates","volume":"98","author":"A Azzi","year":"2001","journal-title":"Blood"},{"issue":"07","key":"ref28","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1537-2995.2006.00866.x","article-title":"Different behavior of erythrovirus B19 and torquetenovirus in response to a single step of albumin purification","volume":"46","author":"A Azzi","year":"2006","journal-title":"Transfusion"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.16311","article-title":"Factor VIII: the protein, cloning its gene, synthetic factor and now - 35 years later - gene therapy; what happened in between?","volume":"189","author":"G Ling","year":"2020","journal-title":"Br J Haematol"},{"issue":"07","key":"ref30","first-page":"441","article-title":"The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?","volume":"2","author":"C D Josephson","year":"2004","journal-title":"Clin Adv Hematol Oncol"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/ejh.12359","article-title":"Innovative approach for improved rFVIII concentrate","volume":"93","author":"M Morfini","year":"2014","journal-title":"Eur J Haematol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pep.2016.09.002","article-title":"Evaluation of the virus clearance capacity and robustness of the manufacturing process for the recombinant factor VIII protein, turoctocog alfa","volume":"129","author":"T W Ellgaard","year":"2017","journal-title":"Protein Expr Purif"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2516.2009.02160.x","article-title":"An improved manufacturing process for Xyntha\/ReFacto AF","volume":"16","author":"B Kelley","year":"2010","journal-title":"Haemophilia"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.2147\/DDDT.S73241","article-title":"A new recombinant factor VIII: from genetics to clinical use","volume":"8","author":"E Santagostino","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.15084","article-title":"Recent advances in developing specific therapies for haemophilia","volume":"181","author":"G Ling","year":"2018","journal-title":"Br J Haematol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ijbiomac.2018.07.164","article-title":"Perspectives on progressive strategies and recent trends in the production of recombinant human factor VIII","volume":"119","author":"S T Mannully","year":"2018","journal-title":"Int J Biol Macromol"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"A Tiede","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.thromres.2012.09.011","article-title":"Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII","volume":"131","author":"C Kannicht","year":"2013","journal-title":"Thromb Res"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41392-022-01016-9","article-title":"Targeted B-domain deletion restores F8 function in human endothelial cells and mice","volume":"7","author":"Z Hu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1365-2516.2009.02026.x","article-title":"Functional roles of the factor VIII B domain","volume":"15","author":"S W Pipe","year":"2009","journal-title":"Haemophilia"},{"issue":"09","key":"ref41","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood-2003-10-3591","article-title":"Bioengineering of coagulation factor VIII for improved secretion","volume":"103","author":"H Z Miao","year":"2004","journal-title":"Blood"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-0037-1612910","article-title":"Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ","volume":"85","author":"H Sandberg","year":"2001","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2516.2009.02027.x","article-title":"Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII","volume":"15","author":"M Recht","year":"2009","journal-title":"Haemophilia"},{"issue":"02","key":"ref44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1365-2516.2005.01068.x","article-title":"B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study","volume":"11","author":"C M Kessler","year":"2005","journal-title":"Haemophilia"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fmed.2019.00261","article-title":"Status of recombinant factor VIII concentrate treatment for hemophilia a in Italy: characteristics and clinical benefits","volume":"6","author":"M Schiavoni","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/hae.13551","article-title":"The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom","volume":"24","author":"M C Mathias","year":"2018","journal-title":"Haemophilia"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1586\/17474086.2014.899896","article-title":"Factor VIII therapy for hemophilia A: current and future issues","volume":"7","author":"L Aledort","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000488060","article-title":"Extended half-life factor VIII and factor IX preparations","volume":"45","author":"L Graf","year":"2018","journal-title":"Transfus Med Hemother"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia","volume":"26","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"100852","DOI":"10.1016\/j.blre.2021.100852","article-title":"Optimising prophylaxis in haemophilia A: the ups and downs of treatment","volume":"50","author":"E Berntorp","year":"2021","journal-title":"Blood Rev"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/jcm11030801","article-title":"Current choices and management of treatment in persons with severe hemophilia A without inhibitors: a mini-Delphi consensus","volume":"11","author":"A Coppola","year":"2022","journal-title":"J Clin Med"},{"issue":"02","key":"ref52","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.thromres.2015.05.005","article-title":"Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII","volume":"136","author":"S Schmidbauer","year":"2015","journal-title":"Thromb Res"},{"issue":"05","key":"ref53","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/hae.12985","article-title":"Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(\u00ae) ) in patients with severe haemophilia A","volume":"22","author":"R Klamroth","year":"2016","journal-title":"Haemophilia"},{"issue":"05","key":"ref54","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood-2016-01-687434","article-title":"Efficacy and safety of rVIII-SingleChain: results of a phase 1\/3 multicenter clinical trial in severe hemophilia A","volume":"128","author":"J Mahlangu","year":"2016","journal-title":"Blood"},{"issue":"09","key":"ref55","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1007\/s12325-021-01853-0","article-title":"Matching-adjusted indirect comparison of efficacy and consumption of rVIII-SingleChain versus two recombinant FVIII products used for prophylactic treatment of adults\/adolescents with severe haemophilia A","volume":"38","author":"S Bonanad","year":"2021","journal-title":"Adv Ther"},{"issue":"02","key":"ref56","doi-asserted-by":"crossref","first-page":"e12665","DOI":"10.1002\/rth2.12665","article-title":"Recombinant single-chain factor VIII in severe hemophilia: long-term safety and efficacy in previously treated patients in the AFFINITY extension study","volume":"6","author":"J Mahlangu","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s11239-021-02599-w","article-title":"Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians","volume":"53","author":"A Borchiellini","year":"2022","journal-title":"J Thromb Thrombolysis"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/asheducation-2016.1.650","article-title":"New therapies for hemophilia","volume":"2016","author":"S W Pipe","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1055\/s-0037-1619772","article-title":"BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation","volume":"32","author":"P L Turecek","year":"2012","journal-title":"Hamostaseologie"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2009-11-254755","article-title":"Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment","volume":"116","author":"B Mei","year":"2010","journal-title":"Blood"},{"key":"ref61","first-page":"115","article-title":"Prolonged effect of N8-Gp in haemophilia A dogs supports less frequent dosing","volume":"9","author":"H Agersoe","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"13","key":"ref62","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1039\/D1NA00119A","article-title":"An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010-2020 review","volume":"3","author":"T Zadeh Mehrizi","year":"2021","journal-title":"Nanoscale Adv"},{"issue":"09","key":"ref63","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"B A Konkle","year":"2015","journal-title":"Blood"},{"issue":"05","key":"ref64","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/hae.13561","article-title":"BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: comprehensive pharmacokinetic assessment from clinical studies","volume":"24","author":"A Shah","year":"2018","journal-title":"Haemophilia"},{"issue":"02","key":"ref65","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hae.13119","article-title":"Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A","volume":"23","author":"E S Mullins","year":"2017","journal-title":"Haemophilia"},{"issue":"02","key":"ref66","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1160\/TH16-06-0444","article-title":"Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A","volume":"117","author":"P Giangrande","year":"2017","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref67","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/jth.14013","article-title":"Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model","volume":"16","author":"F Rode","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref68","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/2040620717746312","article-title":"Novel therapies and current clinical progress in hemophilia A","volume":"9","author":"P Balkaransingh","year":"2018","journal-title":"Ther Adv Hematol"},{"issue":"03","key":"ref69","first-page":"141","article-title":"Extended half-life coagulation factors: a new era in the management of hemophilia patients","volume":"36","author":"M C Ar","year":"2019","journal-title":"Turk J Haematol"},{"issue":"04","key":"ref70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/jcm6040039","article-title":"Outcome of clinical trials with new extended half-life FVIII\/IX concentrates","volume":"6","author":"M E Mancuso","year":"2017","journal-title":"J Clin Med"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"J Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"06","key":"ref72","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jth.12911","article-title":"Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A","volume":"13","author":"G Young","year":"2015","journal-title":"J Thromb Haemost"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1076029619862052","DOI":"10.1177\/1076029619862052","article-title":"Joint bleeding tendencies in adult patients with hemophilia: it's not all pharmacokinetics","volume":"25","author":"J Y Zhou","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"16","key":"ref74","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood.2022017780","article-title":"Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study","volume":"141","author":"L Malec","year":"2023","journal-title":"Blood"},{"issue":"17","key":"ref75","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.2020005250","article-title":"A molecular jewel for hemophilia A treatment","volume":"135","author":"J Rayes","year":"2020","journal-title":"Blood"},{"issue":"17","key":"ref77","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.2019001292","article-title":"BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice","volume":"135","author":"E Seth Chhabra","year":"2020","journal-title":"Blood"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2015.10.038","article-title":"Extension of in vivo half-life of biologically active molecules by XTEN protein polymers","volume":"240","author":"V N Podust","year":"2016","journal-title":"J Control Release"},{"issue":"11","key":"ref79","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"B A Konkle","year":"2020","journal-title":"N Engl J Med"},{"issue":"04","key":"ref80","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"A von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"issue":"04","key":"ref81","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/jth.15257","article-title":"Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products","volume":"19","author":"H Chun","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref83","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hae.13712","article-title":"Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: safety and efficacy results from pathfinder 2 (randomized phase III trial)","volume":"25","author":"N Curry","year":"2019","journal-title":"Haemophilia"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.thromres.2019.12.012","article-title":"Extended half-life recombinant products in haemophilia clinical practice - expectations, opportunities and challenges","volume":"196","author":"P Chowdary","year":"2020","journal-title":"Thromb Res"},{"issue":"04","key":"ref85","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13013","article-title":"The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO","volume":"22","author":"P Collins","year":"2016","journal-title":"Haemophilia"},{"issue":"03","key":"ref86","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/hae.13438","article-title":"Defining extended half-life rFVIII-a critical review of the evidence","volume":"24","author":"J Mahlangu","year":"2018","journal-title":"Haemophilia"},{"issue":"06","key":"ref87","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"L Aledort","year":"2019","journal-title":"Blood Transfus"},{"issue":"03","key":"ref88","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/13543784.2020.1723547","article-title":"Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A","volume":"29","author":"P M Mannucci","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/JBM.S43734","article-title":"Barriers and perceived limitations to early treatment of hemophilia","volume":"4","author":"K Saxena","year":"2013","journal-title":"J Blood Med"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"M E Mancuso","year":"2021","journal-title":"Lancet"},{"issue":"05","key":"ref91","doi-asserted-by":"crossref","first-page":"e0125457","DOI":"10.1371\/journal.pone.0125457","article-title":"Living with, managing and minimising treatment burden in long term conditions: a systematic review of qualitative research","volume":"10","author":"S Demain","year":"2015","journal-title":"PLoS One"},{"issue":"06","key":"ref92","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/17474086.2023.2184341","article-title":"New directions to develop therapies for people with hemophilia","volume":"16","author":"P Gogia","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"02","key":"ref93","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/jth.14660","article-title":"Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)","volume":"18","author":"R Klamroth","year":"2020","journal-title":"J Thromb Haemost"},{"key":"ref94","author":"J Astermark","year":"2010"},{"issue":"10","key":"ref95","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"T Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"02","key":"ref96","doi-asserted-by":"crossref","first-page":"e57479","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Z Sampei","year":"2013","journal-title":"PLoS One"},{"issue":"13","key":"ref97","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"N Uchida","year":"2016","journal-title":"Blood"},{"issue":"21","key":"ref98","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII\u2013mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"M Shima","year":"2016","journal-title":"N Engl J Med"},{"issue":"04","key":"ref99","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/hae.14005","article-title":"Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures","volume":"26","author":"I McCary","year":"2020","journal-title":"Haemophilia"},{"issue":"06","key":"ref100","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors","volume":"25","author":"M Shima","year":"2019","journal-title":"Haemophilia"},{"issue":"24","key":"ref101","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"G Young","year":"2019","journal-title":"Blood"},{"issue":"03","key":"ref102","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"P Knoebl","year":"2021","journal-title":"Blood"},{"issue":"16","key":"ref103","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"M U Callaghan","year":"2021","journal-title":"Blood"},{"issue":"05","key":"ref104","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"A Sehgal","year":"2015","journal-title":"Nat Med"},{"issue":"06","key":"ref105","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-results of the phase 1 inhibitor cohort","volume":"19","author":"K J Pasi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref106","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"A Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"G Young","year":"2023","journal-title":"Lancet"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1182\/blood-2022-167169","article-title":"Fitusiran prophylaxis improves health-related quality of life in people with hemophilia A or B, with or without inhibitors: results of ATLAS-PPX study","volume":"140","author":"G Kenet","year":"2022","journal-title":"Blood"},{"issue":"19","key":"ref109","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood-2013-11-512764","article-title":"Biology of tissue factor pathway inhibitor","volume":"123","author":"J P Wood","year":"2014","journal-title":"Blood"},{"issue":"22","key":"ref110","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"A D Shapiro","year":"2019","journal-title":"Blood"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-139563","article-title":"Risk mitigation strategy for concizumab clinical trials after pause due to non-fatal thrombotic events","volume":"136","author":"S V Seremetis","year":"2020","journal-title":"Blood"},{"issue":"09","key":"ref112","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"T Matsushita","year":"2023","journal-title":"N Engl J Med"},{"issue":"03","key":"ref113","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/a-1175-6530","article-title":"The evolution of hemophilia care: clinical and laboratory advances, opportunities, and challenges","volume":"40","author":"A Trinchero","year":"2020","journal-title":"Hamostaseologie"},{"issue":"09","key":"ref114","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program","volume":"17","author":"G G Levy","year":"2019","journal-title":"J Thromb Haemost"},{"key":"ref115","first-page":"77","article-title":"Anti-TFPI antibody BAY 1093884: early termination of phase II dose escalation study due to thrombosis","volume":"26","author":"F Ferrante","year":"2020","journal-title":"Haemophilia"},{"issue":"19","key":"ref116","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMc1909742","article-title":"Deaths associated with emicizumab in patients with hemophilia A","volume":"381","author":"L M Aledort","year":"2019","journal-title":"N Engl J Med"},{"issue":"07","key":"ref117","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"J I Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref118","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/bloodadvances.2019000849","article-title":"Laboratory monitoring of hemophilia A treatments: new challenges","volume":"4","author":"P J Lenting","year":"2020","journal-title":"Blood Adv"},{"key":"ref119","first-page":"Abstract PB13055","article-title":"Evaluation of emicizumab calibrator and controls with a modified one-stage FVIII assay on an automated coagulation analyzer","volume":"3","author":"S Shinohara","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"07","key":"ref120","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/jth.14430","article-title":"Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence","volume":"17","author":"N C Leksa","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref121","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.3324\/haematol.2018.215129","article-title":"Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement","volume":"104","author":"E Santagostino","year":"2019","journal-title":"Haematologica"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"7","DOI":"10.12688\/f1000research.12491.1","article-title":"Emerging therapies for hemophilia: controversies and unanswered questions","volume":"7","author":"V R Arruda","year":"2018","journal-title":"F1000 Res"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.blre.2019.03.002","article-title":"Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis","volume":"35","author":"B Samuelson Bannow","year":"2019","journal-title":"Blood Rev"},{"issue":"23","key":"ref124","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"P J Lenting","year":"2017","journal-title":"Blood"},{"issue":"03","key":"ref125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4155\/tde-2022-0006","article-title":"Industry update: the latest developments in the field of therapeutic delivery, November 2021","volume":"13","author":"P Timmins","year":"2022","journal-title":"Ther Deliv"},{"issue":"04","key":"ref126","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10545-017-0053-3","article-title":"Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects","volume":"40","author":"J Baruteau","year":"2017","journal-title":"J Inherit Metab Dis"},{"issue":"14","key":"ref127","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.3390\/ijms22147647","article-title":"Gene therapy in hemophilia: recent advances","volume":"22","author":"E C Rodr\u00edguez-Merch\u00e1n","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"K J Pasi","year":"2020","journal-title":"N Engl J Med"},{"key":"ref129","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.omtm.2018.01.004","article-title":"Target-cell-directed bioengineering approaches for gene therapy of hemophilia A","volume":"9","author":"H C Brown","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"01","key":"ref130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nbt.3677","article-title":"Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction","volume":"35","author":"P M Zakas","year":"2017","journal-title":"Nat Biotechnol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood-2019-123666","article-title":"Co-prevalence of pre-existing immunity to different serotypes of adeno-associated virus (AAV) in adults with hemophilia","volume":"134","author":"K Rajavel","year":"2019","journal-title":"Blood"},{"issue":"10","key":"ref132","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"J-C Nault","year":"2015","journal-title":"Nat Genet"},{"issue":"11","key":"ref133","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"M C Ozelo","year":"2022","journal-title":"N Engl J Med"},{"issue":"06","key":"ref134","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"K J Pasi","year":"2021","journal-title":"Haemophilia"},{"issue":"11","key":"ref135","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1016\/j.ymthe.2022.09.020","article-title":"First conditional marketing authorization approval in the European Union for hemophilia \u201cA\u201d gene therapy","volume":"30","author":"T VandenDriessche","year":"2022","journal-title":"Mol Ther"},{"issue":"04","key":"ref136","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1538-7836.2010.03757.x","article-title":"Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring","volume":"8","author":"S Bj\u00f6rkman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hae.13397","article-title":"Individualized PK-based prophylaxis in severe haemophilia","volume":"24","author":"Y Dargaud","year":"2018","journal-title":"Haemophilia"},{"issue":"13","key":"ref138","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"J Oldenburg","year":"2015","journal-title":"Blood"},{"issue":"03","key":"ref139","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/rth2.12106","article-title":"Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations","volume":"2","author":"A Iorio","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"04","key":"ref140","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.blre.2018.01.001","article-title":"Setting the stage for individualized therapy in hemophilia: what role can pharmacokinetics play?","volume":"32","author":"H CAM Hazendonk","year":"2018","journal-title":"Blood Rev"},{"issue":"04","key":"ref141","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.2196\/resprot.6559","article-title":"Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo)","volume":"5","author":"A McEneny-King","year":"2016","journal-title":"JMIR Res Protoc"},{"issue":"03","key":"ref142","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/hae.14295","article-title":"A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa","volume":"27","author":"A Arvanitakis","year":"2021","journal-title":"Haemophilia"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"101098","DOI":"10.1016\/j.blre.2023.101098","article-title":"The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators","volume":"61","author":"T MHJ Goedhart","year":"2023","journal-title":"Blood Rev"},{"issue":"04","key":"ref144","doi-asserted-by":"crossref","first-page":"570","DOI":"10.25122\/jml-2022-0103","article-title":"Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A","volume":"15","author":"A Batorova","year":"2022","journal-title":"J Med Life"},{"issue":"05","key":"ref145","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/hae.13251","article-title":"PK-guided personalized prophylaxis with Nuwiq\u00ae (human-cl rhFVIII) in adults with severe haemophilia A","volume":"23","author":"T Lissitchkov","year":"2017","journal-title":"Haemophilia"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"2634853521991517","DOI":"10.1177\/2634853521991517","article-title":"Efficacy of Nuwiq\u00ae (Simoctocog Alfa) in patients with hemophilia A who changed and adhered to a pharmacokinetic-guided prophylaxis regimen in the NuPreviq Study","volume":"14","author":"K J Pasi","year":"2021","journal-title":"Clin Med Insights Blood Disord"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.thromres.2018.11.017","article-title":"Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing","volume":"173","author":"A Nagao","year":"2019","journal-title":"Thromb Res"},{"issue":"04","key":"ref148","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000521360","article-title":"Efficacy of individualized preventive treatment of patients with severe hemophilia A guided by multiple clinical parameters and pharmacokinetics","volume":"145","author":"Y Wang","year":"2022","journal-title":"Acta Haematol"},{"issue":"07","key":"ref149","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/jth.14153","article-title":"Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH","volume":"16","author":"M V Ragni","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref150","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/rth2.12118","article-title":"Focusing in on use of pharmacokinetic profiles in routine hemophilia care","volume":"2","author":"S E Croteau","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"12","key":"ref151","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1111\/jth.15106","article-title":"Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation","volume":"18","author":"L LFG Valke","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref152","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2010.029868","article-title":"A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A","volume":"96","author":"K Fischer","year":"2011","journal-title":"Haematologica"},{"issue":"03","key":"ref153","first-page":"316","article-title":"Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis","volume":"27","author":"S E Croteau","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"08","key":"ref154","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/2040620718785363","article-title":"Clinicopathological parameters influencing inhibitor development in patients with hemophilia A receiving on-demand therapy","volume":"9","author":"S Arshad","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/hae.12993","article-title":"Preventing bleeds by treatment: new era for haemophilia changing the paradigm","volume":"22","author":"H Marijke van den Berg","year":"2016","journal-title":"Haemophilia"},{"issue":"01","key":"ref156","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40199-020-00347-8","article-title":"Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A","volume":"28","author":"F Lotfi","year":"2020","journal-title":"Daru"},{"issue":"02","key":"ref157","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14737167.2020.1789457","article-title":"Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain","volume":"21","author":"H K Kim","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref158","author":"N Gomes","year":"2023"},{"issue":"10","key":"ref159","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1080\/14740338.2016.1208747","article-title":"The safety of pharmacologic options for the treatment of persons with hemophilia","volume":"15","author":"M Franchini","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"24","key":"ref160","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/bloodadvances.2019000848","article-title":"Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream","volume":"3","author":"J Neumeyer","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"ref161","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/2040620717721458","article-title":"Current and emerging factor VIII replacement products for hemophilia A","volume":"8","author":"L A Cafuir","year":"2017","journal-title":"Ther Adv Hematol"},{"issue":"08","key":"ref162","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/ph15080911","article-title":"Immunogenicity of current and new therapies for hemophilia A","volume":"15","author":"A NL Prezotti","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/S0140-6736(23)00514-7","article-title":"Fitusiran in haemophilia: a breakthrough drug with many unknowns","volume":"401","author":"F Peyvandi","year":"2023","journal-title":"Lancet"},{"issue":"01","key":"ref164","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12929-021-00760-4","article-title":"Advances in the management of haemophilia: emerging treatments and their mechanisms","volume":"28","author":"D Okaygoun","year":"2021","journal-title":"J Biomed Sci"},{"issue":"12","key":"ref165","first-page":"583","article-title":"Treatment of haemophilia: from replacement to gene therapy","volume":"157","author":"J A P\u00e1ramo","year":"2021","journal-title":"Med Clin"},{"issue":"12","key":"ref166","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1080\/03007995.2019.1649378","article-title":"Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial","volume":"35","author":"A Reyes","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"09","key":"ref167","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14712598.2022.2002842","article-title":"Hemophilia A gene therapy: current and next-generation approaches","volume":"22","author":"S W Pipe","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"17","key":"ref168","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"J McIntosh","year":"2013","journal-title":"Blood"},{"issue":"02","key":"ref169","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood-2010-03-274233","article-title":"Go long! A touchdown for factor VIII?","volume":"116","author":"S W Pipe","year":"2010","journal-title":"Blood"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1778103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:18:15Z","timestamp":1730805495000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1778103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":165,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2024,6,11]]},"published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1778103","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]}}}